Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? | Zendy

Sara Baldelli | Zendy; Mario Corbellino | Zendy; Emilio Clementi | Zendy; Dario Cattaneo | Zendy; Cristina Gervasoni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

Author(s) -

Sara Baldelli,

Mario Corbellino,

Emilio Clementi,

Dario Cattaneo,

Cristina Gervasoni

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa190

Subject(s) - lopinavir , lopinavir/ritonavir , covid-19 , ritonavir , virology , medicine , pandemic , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , infectious disease (medical specialty) , disease , outbreak

Unit of Clinical Pharmacology, Fatebenefratelli Sacco University Hospital, Milan, Italy; 3rd Division of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy; Unit of Clinical Pharmacology, Fatebenefratelli Sacco University Hospital, Department of Biomedical and Clinical Sciences L. Sacco, Università di Milano, Milan, Italy; IRCCS E, Nedea Scientific Institute, Bosisio Parini, Italy; Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research